Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
Jütte H, Reike M, Wirtz RM, Kriegmair M, Erben P, Tully K, Weyerer V, Eckstein M, Hartmann A, Eidt S, Wezel F, Bolenz C, Tannapfel A, Noldus J, Roghmann F. Jütte H, et al. Among authors: eidt s. J Pers Med. 2021 May 26;11(6):473. doi: 10.3390/jpm11060473. J Pers Med. 2021. PMID: 34073233 Free PMC article.
Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
Wirtz RM, Sihto H, Isola J, Heikkilä P, Kellokumpu-Lehtinen PL, Auvinen P, Turpeenniemi-Hujanen T, Jyrkkiö S, Lakis S, Schlombs K, Laible M, Weber S, Eidt S, Sahin U, Joensuu H. Wirtz RM, et al. Among authors: eidt s. Breast Cancer Res Treat. 2016 Jun;157(3):437-46. doi: 10.1007/s10549-016-3835-7. Epub 2016 May 24. Breast Cancer Res Treat. 2016. PMID: 27220750 Free PMC article.
Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, Stöhr R, Eidt S, Hartmann A, Wirtz RM, Sahin U. Laible M, et al. Among authors: eidt s. BMC Cancer. 2016 Jul 7;16:398. doi: 10.1186/s12885-016-2476-x. BMC Cancer. 2016. PMID: 27389414 Free PMC article.
ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.
Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium. Breyer J, et al. Among authors: eidt s. Urol Int. 2017;98(3):282-289. doi: 10.1159/000453670. Epub 2016 Dec 17. Urol Int. 2017. PMID: 27992871
In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium. Breyer J, et al. Among authors: eidt s. Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10. Virchows Arch. 2017. PMID: 28074276
A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.
Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P. Eckstein M, et al. Among authors: eidt s. Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13. Oncotarget. 2018. PMID: 29599921 Free PMC article.
75 results